Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the First and Only Drug FDA Approved for the Management of Ventricular Hypertrophy in Cats with Subclinical Hypertrophic Cardiomyopathy (HCM), A Condition Affecting as Many as One in Seven Cats

Contributed by: Business Wire

Logo

Tags

Veterinary

FDA

Pets

Clinical Trials

Cardiology

Biotechnology

Health

Consumer

Pharmaceutical

PBI-Gordon Companies, Inc.

More Like This

PBI-Gordon Companies, Inc. Calls on Petspan to Cease and Desist False and Misleading Advertisement, Promotion and Sale of Compounded Rapamycin (Sirolimus) for HCM in Cats

PR Newswire associated0

Boehringer Ingelheim launches VETMEDIN® Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Pharmanovia Signs Novel Biologic In-Licensing Agreement With Lindis Biotech to Commercialise Catumaxomab for Treatment of Rare Condition, Malignant Ascites

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

Business Wire associated0

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

UK approves finerenone for a common form of chronic heart failure

PR Newswire associated0

Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease

PR Newswire associated0

Cresilon Announces International Distribution Agreement for VETIGEL with Covetrus